Literature DB >> 1720738

Intravenous infusion of iloprost in arterial occlusive disease: dose-dependent effects on skin microcirculation.

L Caspary1, A Creutzig, K Alexander.   

Abstract

Transcutaneous oxygen pressure (tcPo2), laser Doppler flux and capillary microscopy have been used to examine the forefoot skin in 5 healthy men and 8 patients with severe peripheral arterial occlusive disease in order to evaluate the dose dependent effects of iloprost on skin microcirculation. Iloprost was infused IV starting at 0.0625 ng.kg-1.min-1 and doubling the dose every 15 min up to 2 ng.kg-1.min-1. While tcPo2 at an electrode core temperature of 44 degrees C decreased in both patients and controls, there was a significant dose dependent increase in tcPo2 (37 degrees C) in the controls from 0.25 ng.kg-1.min-1. In the patients the reaction was variable: it was decreased in two and increased in 6, with a maximum either at 0.25-0.5 ng.kg-1.min-1 (n = 3) or at the highest dose (1.0 or 2.0 ng.kg-1.min-1; n = 3). Mean laser Doppler flux in both groups was increased, although the reaction was not consistent in the patients. Density of forefoot skin capillaries was reduced in 3 patients, and in the others the flow velocity was very low. During infusion of iloprost, both an increase in capillary density and blood cell velocity were observed. The effects were of variable intensity and occurred at varying doses, some appeared early and diminished as the dose was increased, and others were found only at 2 ng.kg-1.min-1. Adverse effects were numerous, extending from harmless skin flushing to mental changes and a quickly reversible attack of angina pectoris.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1720738     DOI: 10.1007/BF00265905

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  23 in total

1.  [Effects of iloprost on circulation at rest and metabolism in the extremities of healthy probands in relation to dose and mode of administration].

Authors:  W Rexroth; M Hüpen; E Wagner; R Hild
Journal:  Vasa       Date:  1987       Impact factor: 1.961

2.  Use of stable prostacyclin analogue ZK 36 374 to treat severe lower limb ischaemia.

Authors:  R Chiesa; A Vicari; G Mari; M Galimberti; V Di Carlo; G Pozza
Journal:  Lancet       Date:  1985-07-13       Impact factor: 79.321

3.  Pharmacokinetics and pharmacodynamics of the prostacyclin analogue iloprost in man.

Authors:  W Krause; T Krais
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

4.  Clinical effects of intravenous iloprost in patients with intermittent claudication.

Authors:  U Müller-Bühl; C Diehm; T Krais; R Zimmermann; H Mörl; H H Eckstein
Journal:  Eur J Clin Pharmacol       Date:  1987       Impact factor: 2.953

5.  [Transcutaneous pO2 and laser Doppler flux in increasing doses of intraarterial and intravenously administered prostaglandin E1].

Authors:  A Creutzig; L Caspary; C Ranke; D Kiessling; J Wilkens; J Frölich; K Alexander
Journal:  Vasa       Date:  1987       Impact factor: 1.961

6.  Comparison of Laser-Doppler-Flux and tcPO2 in healthy probands and patients with arterial ischemia.

Authors:  L Caspary; A Creutzig; K Alexander
Journal:  Adv Exp Med Biol       Date:  1987       Impact factor: 2.622

7.  Spatial and temporal variations in human skin blood flow.

Authors:  T Tenland; E G Salerud; G E Nilsson; P A Oberg
Journal:  Int J Microcirc Clin Exp       Date:  1983

8.  An instrument to measure cutaneous blood flow using the Doppler shift of laser light.

Authors:  D Watkins; G A Holloway
Journal:  IEEE Trans Biomed Eng       Date:  1978-01       Impact factor: 4.538

9.  [Iloprost, a stable prostacyclin derivative, in stage 4 arterial occlusive disease. A placebo-controlled multicenter study].

Authors:  C Diehm; O Abri; G Baitsch; G Bechara; K Beck; H K Breddin; F E Brock; H D Clevert; D Corovic; M Marshall
Journal:  Dtsch Med Wochenschr       Date:  1989-05-19       Impact factor: 0.628

10.  Hemodynamic effects of iloprost, a prostacyclin analog.

Authors:  S Kaukinen; P Ylitalo; T Pessi; H Vapaatalo
Journal:  Clin Pharmacol Ther       Date:  1984-10       Impact factor: 6.875

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.